医脉通导读2025年6月30日，替尔泊肽注射液正式获得中国国家药品监督管理局（NMPA）批准，成为首个且目前唯一一个适用于治疗成人肥胖患者的中重度阻塞性睡眠呼吸暂停（OSA）的处方药。替尔泊肽可改善中度至重度阻塞性睡眠呼吸暂停肥胖成人患者的睡眠障碍。

阻塞性睡眠呼吸暂停是一种常见的睡眠障碍，主要表现为在睡眠过程中反复出现呼吸暂停。这种疾病在30至69岁的人群中尤为普遍，全球估计有4.25亿人患有中度至重度OSA。仅在中国，患者人数就高达1.76亿，形势可谓严峻。OSA不仅影响患者的睡眠质量，还会引发一系列健康问题。研究表明，OSA患者发生中风的概率是普通人的4.33倍，病死率则是普通人的1.98倍。

Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

Taking to platforms including Reddit and Telegram for guidance, buyers import small quantities, often described as research ...

Investing.com - H.C. Wainwright维持对Scholar Rock (NASDAQ: SRRK )的买入评级和50.00美元的目标价，该公司股价在过去一年中飙升337%，仅在上周就上涨了12%。这一评级是基于公司最近的EMBRAZE二期临床试验结果。

GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain ...

A recent study published in the Journal of the American Dental Association found that Tirzepatide presented a novel strategy ...

The World Health Organization continues its investigation into the origins of COVID-19, with significant information still needed. Concurrently, Americans like Amy Spencer are crafting their own ...